Latest Asx News

Actinogen Medical has obtained positive scientific advice from the European Medicines Agency that aligns with prior FDA guidance, clarifying regulatory requirements for its Alzheimer’s drug Xanamem and paving the way for a streamlined approval process in major markets.

Terragen Holdings secures a landmark supply agreement for its probiotic and biostimulant products with Ravensworth Feedlot, alongside a $2.8 million funded trial at Mort & Co’s Grassdale feedlot to validate its probiotic’s impact on cattle performance.

Viking Mines reports a major metallurgical breakthrough at its Linka Tungsten Project, achieving a 62.5% WO3 concentrate at 59.8% recovery using combined gravity and flotation processing on a larger 10 kg sample, significantly improving previous results and validating a low-capex flowsheet ahead of maiden drilling.

Nexalis Therapeutics has locked in a $53 million non-dilutive funding facility with Point8 Capital, replacing its previous lender and supporting three clinical programs targeting breakthrough cancer pain, panic disorder, and treatment-resistant depression.

BPH Global Ltd (ASX: BP8) posted its second best monthly seaweed trading result with gross sales of approximately A$391,000 in the twelfth month, pushing aggregate sales beyond A$3.3 million as Indonesian operations scale up post-monsoon.

The Therapeutic Goods Administration has broadened the range of clinicians eligible to participate in psychedelic-assisted psychotherapy, a move set to speed up recruitment and improve patient access across Emyria’s national Empax network.

Li-FT Power Ltd. has released an extensive update to its Corporate Governance Statement, outlining its board structure, committee roles, and compliance with Canadian and ASX governance standards. The company highlights partial adherence to some ASX recommendations, reflecting its current development stage.

Imugene has dosed the first patient in a new cohort combining its azer-cel CAR T therapy with BTK inhibitors, targeting patients with B-cell malignancies who failed prior BTKi treatment. This move broadens the trial’s scope and tackles a significant unmet need in blood cancer therapy.

Peet Limited has upgraded its FY26 net profit guidance by up to 17%, driven by accelerated construction and robust market demand in Western Australia and Queensland.

Aspermont Limited (ASX:ASP) reported a 147% jump in net profit and 11% revenue growth for H1 FY26, driven by steady subscription growth and a ramp-up in non-subscription revenues. The company’s self-funded data and intelligence platform is on track, with Rio Tinto’s enterprise contract validating its strategic pivot.

Develop Global’s Pioneer Dome lithium project hits high-grade infill drilling results surpassing resource expectations, setting the stage for a Final Investment Decision next month on an 850,000-tonne DSO operation.

Beonic Ltd (ASX:BEO) has initiated a $3 million pro-rata renounceable entitlement offer at $0.08 per share, partially underwritten by Alpine Capital, to shore up working capital and repay shareholder loans. The offer carries potential dilution of 35.7% for non-participating shareholders and may increase the Thorney Group's voting power significantly.